ArticleJournal for immunotherapy of cancer2026

AdvanTIG-105: a phase I/Ib dose-expansion study of ociperlimab plus tislelizumab with or without chemotherapy in metastatic non-small cell lung cancer and extensive-stage small cell lung cancer.

Shun Lu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.